AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 163625 — intervention group
Group type: COMPARATOR
Intervention: Detoxification and after-care services (mean length of stay nine days)
Number of subjects: 58
Study 30882901 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized index node removal after neoadjuvant immunotherapy
Number of subjects: 0
Study 30882901 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant immunotherapy
Number of subjects: 0
Study 29206627 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer plus website (goal-setting, feedback, disease-specific education, online community forum)
Number of subjects: 109
Study 29206627 — intervention group
Group type: COMPARATOR
Intervention: Pedometer alone
Number of subjects: 109
Study 25303096 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention programme (fitness training and counselling on physical behaviour and sports participation) for 6 months
Number of subjects: 57
Study 25303096 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention programme
Number of subjects: 57
Study 23138384 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (imaging delay 4 s, 48 ml contrast medium)
Number of subjects: 29
Study 23138384 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (imaging delay 8 s, 64 ml contrast medium)
Number of subjects: 29
Study 23138384 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol C (imaging delay 12 s, 80 ml contrast medium)
Number of subjects: 29
Study 21752507 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical removal of impacted lower third molars
Number of subjects: 285
Study 19404219 — intervention group
Group type: EXPERIMENTAL
Intervention: PLCO intervention arm (screening for lung cancer)
Number of subjects: 77465
Study 19404219 — intervention group
Group type: EXPERIMENTAL
Intervention: Model including predictors (older age, lower education, smoking history, etc.)
Number of subjects: 77465
Study 19404219 — intervention group
Group type: EXPERIMENTAL
Intervention: Model excluding smoking variables
Number of subjects: 77465
Study 19404219 — intervention group
Group type: EXPERIMENTAL
Intervention: Model excluding all nonradiographic variables
Number of subjects: 77465
Study 16650679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmic care personnel (including retina specialists, general ophthalmologists, nurses, and photographers) reading digital fundus images without additional training
Number of subjects: 12
Study 16650679 — intervention group
Group type: EXPERIMENTAL
Intervention: Retina specialists reading digital fundus images
Number of subjects: 12
Study 16650679 — intervention group
Group type: COMPARATOR
Intervention: All readers compared with consensus of retina specialists
Number of subjects: 12
Study 16650679 — intervention group
Group type: EXPERIMENTAL
Intervention: Retina specialist group
Number of subjects: 12
Study 15453547 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon (10 mg)
Number of subjects: 12
Study 15453547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11288794 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/daily)
Number of subjects: 40
Study 11288794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11288794 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 9248374 — intervention group
Group type: EXPERIMENTAL
Intervention: Moi‐Stir swabs
Number of subjects: 0
Study 9248374 — intervention group
Group type: COMPARATOR
Intervention: Lemon glycerin swabs
Number of subjects: 0
Study 9248374 — intervention group
Group type: COMPARATOR
Intervention: Toothettes (pink sponge applicators) and water
Number of subjects: 0
Study 8308716 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) capsules containing 20.0 mg
Number of subjects: 8
Study 8308716 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) capsules containing 40.0 mg
Number of subjects: 8
Study 8308716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8308716 — intervention group
Group type: COMPARATOR
Intervention: Conventional ISDN tablets (5.0 mg each)
Number of subjects: 8
Study 3822497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 2
Study 3822497 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral mexiletine
Number of subjects: 2
Study 3822497 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 2
Study 31680344 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral/panoramic view capsule (CapsoCam Plus)
Number of subjects: 25
Study 31680344 — intervention group
Group type: COMPARATOR
Intervention: Axial view capsule (PillCam SB3)
Number of subjects: 25
Study 29746376 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 subtype A
Number of subjects: 308
Study 29746376 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 subtype D
Number of subjects: 308
Study 29746376 — intervention group
Group type: COMPARATOR
Intervention: HIV exposed uninfected
Number of subjects: 308
Study 28836993 — intervention group
Group type: COMPARATOR
Intervention: Flucloxacillin 500 mg four times daily and placebo
Number of subjects: 0
Study 28836993 — intervention group
Group type: EXPERIMENTAL
Intervention: Flucloxacillin 500 mg four times daily and phenoxymethylpenicillin 500 mg four times daily
Number of subjects: 0
Study 25625133 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable bulk-fill resin composite SDR
Number of subjects: 86
Study 25625133 — intervention group
Group type: COMPARATOR
Intervention: Resin composite CeramX mono+ only
Number of subjects: 86
Study 25625133 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II restorations with SDR-CeramX mono+
Number of subjects: 86
Study 25625133 — intervention group
Group type: COMPARATOR
Intervention: Class II restorations with CeramX mono+ only
Number of subjects: 86
Study 23122973 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle relaxant (Group MR)
Number of subjects: 120
Study 23122973 — intervention group
Group type: COMPARATOR
Intervention: No muscle relaxant (Group NMR)
Number of subjects: 120
Study 23122973 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 120
Study 21821642 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki treatment
Number of subjects: 21
Study 21821642 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 21
Study 18673078 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga group
Number of subjects: 80
Study 18673078 — intervention group
Group type: COMPARATOR
Intervention: Control group (physical exercise)
Number of subjects: 80
Study 16309684 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 1398
Study 16309684 — intervention group
Group type: EXPERIMENTAL
Intervention: Last Menstruation Period (LMP)
Number of subjects: 1398
Study 16309684 — intervention group
Group type: EXPERIMENTAL
Intervention: First Fundal Height (FH(1))
Number of subjects: 1398
Study 16309684 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm (reference GA)
Number of subjects: 1398
Study 12775735 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily
Number of subjects: 916
Study 12775735 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg daily
Number of subjects: 916
Study 10852793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil (8 mg)
Number of subjects: 24
Study 10852793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10852793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil
Number of subjects: 24
Study 9374925 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine (SSZ) 2000 mg daily (maximum 3000 mg)
Number of subjects: 105
Study 9374925 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 7.5 mg weekly (maximum 15 mg)
Number of subjects: 105
Study 9374925 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sulphasalazine and methotrexate (COMBI)
Number of subjects: 105
Study 1525791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor AF (750 mg twice daily)
Number of subjects: 266
Study 1525791 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (500 mg three times daily)
Number of subjects: 266
Study 1525791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor AF
Number of subjects: 266
Study 1525791 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 266
Study 3903579 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ritodrine therapy
Number of subjects: 0
Study 3903579 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31237964 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain at five to seven sites
Number of subjects: 450
Study 31237964 — intervention group
Group type: COMPARATOR
Intervention: Pain at zero to two sites
Number of subjects: 450
Study 29767743 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat yogurt (339 g)
Number of subjects: 120
Study 29767743 — intervention group
Group type: COMPARATOR
Intervention: Soy pudding (324 g)
Number of subjects: 120
Study 25777794 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental support device (DSD)
Number of subjects: 191
Study 25777794 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DSD)
Number of subjects: 191
Study 24357420 — intervention group
Group type: EXPERIMENTAL
Intervention: IV 2% lignocaine from induction until 1 h after surgery
Number of subjects: 50
Study 24357420 — intervention group
Group type: COMPARATOR
Intervention: IP 0.2% lignocaine instillation in gallbladder fossa after removal of gallbladder
Number of subjects: 50
Study 22607109 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 50 μg/mL
Number of subjects: 282
Study 22607109 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 75 μg/mL
Number of subjects: 282
Study 22607109 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 100 μg/mL
Number of subjects: 282
Study 22607109 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 125 μg/mL
Number of subjects: 282
Study 21121402 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 mcg, 6 hourly, max 4 doses)
Number of subjects: 258
Study 21121402 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 258
Study 21121402 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 258
Study 21121402 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol
Number of subjects: 258
Study 17407170 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% carbon dioxide challenge test
Number of subjects: 83
Study 17407170 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral caffeine (480 mg) intake
Number of subjects: 83
Study 17407170 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive group (patients who had a panic attack during both tests)
Number of subjects: 83
Study 16363297 — intervention group
Group type: EXPERIMENTAL
Intervention: Small volume at high concentration (5 mL of 0.75% levobupivacaine)
Number of subjects: 69
Study 16363297 — intervention group
Group type: COMPARATOR
Intervention: Large volume at low concentration (10 mL of 0.375% levobupivacaine)
Number of subjects: 69
Study 16427409 — intervention group
Group type: EXPERIMENTAL
Intervention: Twist drill craniostomy
Number of subjects: 79
Study 16427409 — intervention group
Group type: COMPARATOR
Intervention: Bur hole or craniotomy
Number of subjects: 79
Study 10775784 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-component blood-stage malaria vaccine (recombinant proteins MSP1, MSP2, RESA with Montanide ISA720 adjuvant), injected twice (four weeks apart)
Number of subjects: 12
Study 10775784 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant alone
Number of subjects: 12
Study 8685289 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual oriented psychosocial intervention (IPI)
Number of subjects: 76
Study 8685289 — intervention group
Group type: COMPARATOR
Intervention: Individual oriented psychosocial intervention plus behavioral family intervention (IPFI)
Number of subjects: 76
Study 8685289 — intervention group
Group type: EXPERIMENTAL
Intervention: In‐patient treatment with psychoeducation for parents followed by out‐patient psychosocial intervention
Number of subjects: 76
Study 8685289 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional family intervention
Number of subjects: 76
Study 1519714 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (5 mg.kg‐1)
Number of subjects: 60
Study 1519714 — intervention group
Group type: COMPARATOR
Intervention: Tubocurarine (3 mg)
Number of subjects: 60
Study 1519714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 60
Study 6524312 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1%, 1.0%, and 10% phenylephrine eye drops
Number of subjects: 30
Study 6524312 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine treatment
Number of subjects: 30
Study 6524312 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study 31232721 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estrogen (via ring or cream)
Number of subjects: 35
Study 31232721 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 35
Study 31565781 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational drug
Number of subjects: 400
Study 31565781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 30954205 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) applied to one side after osteotomy and before fixation
Number of subjects: 21
Study 30954205 — intervention group
Group type: COMPARATOR
Intervention: Control side (no PRF applied)
Number of subjects: 21
Study 26852139 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifampridine phosphate (Firdapse(®))
Number of subjects: 0
Study 26852139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25372452 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% povidone‐iodine
Number of subjects: 70
Study 25372452 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine in an alcohol base (Chemisol)
Number of subjects: 70
Study 22745272 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO-α (n=36)
Number of subjects: 72
Study 22745272 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=36)
Number of subjects: 72
Study 21244725 — intervention group
Group type: EXPERIMENTAL
Intervention: PURETHAL Mites (PM)
Number of subjects: 140
Study 21244725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 18036873 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin infusion followed by standard light application at 15 minutes
Number of subjects: 60
Study 18036873 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin infusion followed by delayed light application at 30 minutes
Number of subjects: 60
Study 16282835 — intervention group
Group type: EXPERIMENTAL
Intervention: PAX + sulpiride (100 mg/d)
Number of subjects: 41
Study 16282835 — intervention group
Group type: COMPARATOR
Intervention: PAX (10-40 mg/d)
Number of subjects: 41
Study 11902848 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Works for Women (HWW) intervention
Number of subjects: 538
Study 11902848 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (control)
Number of subjects: 538
Study 10411058 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral occlusive device (FemAssist)
Number of subjects: 57
Study 7744584 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of chemotherapy and endocrine manipulation for node-negative breast cancer
Number of subjects: 0
Study 7744584 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy for node-positive disease
Number of subjects: 0
Study 7744584 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed reintroduction of chemotherapy after initial cytotoxic treatment for node-positive disease
Number of subjects: 0
Study 7744584 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection for elderly patients
Number of subjects: 0
Study 7744584 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment for breast cancer
Number of subjects: 0
Study 7744584 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological findings in node-negative disease
Number of subjects: 0
Study 7744584 — intervention group
Group type: EXPERIMENTAL
Intervention: c-erbB-2 oncogene expression
Number of subjects: 0
Study 7744584 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns of relapse
Number of subjects: 0
Study 31668965 — intervention group
Group type: EXPERIMENTAL
Intervention: Renshen Yangrong Tang (RSYRT) herbal extract granules, taken twice a day for six weeks.
Number of subjects: 83
Study 31668965 — intervention group
Group type: EXPERIMENTAL
Intervention: Renshen Yangrong Tang (RSYRT) herbal extract granules.
Number of subjects: 83
Study 31668965 — intervention group
Group type: COMPARATOR
Intervention: Control group (low dose of a single herb - huangqi, taken twice a day for six weeks).
Number of subjects: 83
Study 31703669 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment of HCV in PWID, which includes testing for HCV, assessing liver fibrosis, counselling, treatment delivery, follow-up, and evaluation in integrated substance use disorder treatment clinics.
Number of subjects: 200
Study 31703669 — intervention group
Group type: COMPARATOR
Intervention: Standard care involving referral to further diagnostics, treatment, and treatment follow-up in a hospital outpatient clinic.
Number of subjects: 200
Study 31703669 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment of HCV in PWID.
Number of subjects: 200
Study 31703669 — intervention group
Group type: COMPARATOR
Intervention: Standard care.
Number of subjects: 200
Study 28625661 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle loading (IML) in normoxia
Number of subjects: 10
Study 28625661 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle loading (IML) in hypoxia
Number of subjects: 10
Study 28625661 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia compared to normoxia
Number of subjects: 10
Study 26020764 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of diabetes mellitus
Number of subjects: 31227
Study 26020764 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline fasting plasma glucose value increase by 1 mmol/L
Number of subjects: 31227
Study 26020764 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline fasting plasma glucose value increase by 1 mmol/L (after adjustment)
Number of subjects: 31227
Study 24016248 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin-benzafibrate combination therapy (atorvastatin 20 mg QN + bezafibrate 200 mg BID)
Number of subjects: 104
Study 24016248 — intervention group
Group type: COMPARATOR
Intervention: Statin monotherapy (atorvastatin 20 mg QN or equivalent)
Number of subjects: 104
Study 24016248 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin-benzafibrate combination therapy
Number of subjects: 104
Study 24016248 — intervention group
Group type: COMPARATOR
Intervention: Statin monotherapy
Number of subjects: 104
Study 21446859 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training 2 days per week for 10 weeks
Number of subjects: 30
Study 18596116 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (10 mg daily for 6 weeks)
Number of subjects: 87
Study 18596116 — intervention group
Group type: COMPARATOR
Intervention: Lithium (control group)
Number of subjects: 87
Study 18596116 — intervention group
Group type: COMPARATOR
Intervention: Alternate psychotropic medications (control group)
Number of subjects: 87
Study 15764730 — intervention group
Group type: COMPARATOR
Intervention: Arterial Hb‐CO concentrations in patients at stable conditions
Number of subjects: 58
Study 15764730 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial Hb‐CO concentrations in patients at exacerbations
Number of subjects: 58
Study 15764730 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial Hb‐CO concentrations in patients at stage III
Number of subjects: 58
Study 15764730 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial Hb‐CO concentrations in patients at stage IV
Number of subjects: 58
Study 15764730 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial Hb‐CO
Number of subjects: 58
Study 15764730 — intervention group
Group type: COMPARATOR
Intervention: Arteriovenous Hb‐CO differences in patients at exacerbations
Number of subjects: 58
Study 12352887 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole solution (200 mg every 12 hr)
Number of subjects: 188
Study 12352887 — intervention group
Group type: COMPARATOR
Intervention: Intravenous/oral fluconazole (400 mg every 24 hr)
Number of subjects: 188
Study 12352887 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole solution
Number of subjects: 188
Study 12352887 — intervention group
Group type: COMPARATOR
Intervention: Intravenous/oral fluconazole
Number of subjects: 188
Study 10224587 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail intervention
Number of subjects: 136
Study 10224587 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail plus telephone intervention
Number of subjects: 136
Study 10224587 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 136
Study 8852867 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg baclofen
Number of subjects: 7
Study 8852867 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mg baclofen
Number of subjects: 7
Study 1839722 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine treatment (ethyl cellulose containing chlorhexidine)
Number of subjects: 30
Study 1839722 — intervention group
Group type: COMPARATOR
Intervention: Placebo polymer
Number of subjects: 30
Study 1839722 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study 6662171 — intervention group
Group type: EXPERIMENTAL
Intervention: slow-release disopyramide phosphate (DR) 300 mg twice daily
Number of subjects: 12
Study 6662171 — intervention group
Group type: COMPARATOR
Intervention: long-acting propranolol (PR) 1 X 160 mg daily
Number of subjects: 12
Study 31689943 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose beverage (GI 32)
Number of subjects: 70
Study 31689943 — intervention group
Group type: COMPARATOR
Intervention: Sucrose beverage (GI 65)
Number of subjects: 70